Background Despite advances in early detection and therapies, cancer is still one of the
most common causes of death worldwide. Since each tumor is unique, there is a need to …

Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that
originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as …

Colorectal cancer (CRC) is still a leading cause of cancer death worldwide. Less than half of
cases are diagnosed when the cancer is locally advanced. CRC is a heterogenous disease …

Immunotherapy has revolutionized colon cancer treatment. Immune checkpoint inhibitors
(ICIs) have shown clinical benefits for colon cancer patients, especially those with high …

Colorectal cancer (CRC) is a leading cause of death worldwide, despite progress made in
detection and management through surgery, chemotherapy, radiotherapy, and …

PURPOSE More than 50% of patients with stage IV colorectal cancer (metastatic colorectal
cancer [mCRC]) relapse postresection. The efficacy of postoperative systemic treatment is …

Colorectal cancer (CRC) is the second most common cause of cancer death in the world.
Both modifiable and nonmodifiable risk factors play a significant role in the pathogenesis of …

Multiplex assays, involving the simultaneous use of multiple circulating tumor DNA (ctDNA)
markers, can improve the performance of liquid biopsies so that they are highly predictive of …

Currently, there is a crucial need for novel diagnostic and prognostic biomarkers with high
specificity and sensitivity in patients with colorectal cancer. A “liquid biopsy” is characterized …

Colorectal carcinoma (CRC) is the third most common cancer in terms of diagnosis and the
second in terms of mortality. Recent studies have shown that various proteins, extracellular …